The result aligns to some extent with previous ante-mortem imaging of greater baseline temporo-parietal tau PET binding as a predictor of cognitive decline in AD.21,54 Our findings, although tentative, emerged from quantitative pathological assessment and as such, may have stronger support for the administration of disease-modifying therapies that target amyloid-β and HP-tau across the spectrum of neurodegenerative dementias, and speak to the major push toward targeting amyloid-β in preclinical AD trials.55 The gene discussed is MAPT; the disease is Alzheimer disease.